Exclusive Interviews

Dr. Todd Hobbs discusses diabetes and obesity related projects at Novo Nordisk, including the results of the DEVOTE trial: the cardiovascular outcomes trial for degludec, basal insulin.

n this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about data from various important trials as well as the importance of their unique product degludec.

In part 1 of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about his work at Novo Nordisk not only as chief medical officer but also as a person with type 1.

In part 2 of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about DEVOTE data and how degludec works.

In part 3 of this Exclusive Interview, Dr. Todd Hobbs explains the DUAL-7 data in a converstion with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.

In part 4 of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about the GLP-1 cardiovascular trials and the significance of the LEADER study.

In part 5, the conclusion, of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about what's in the pipeline for Novo Nordisk and smart insulin.

Drs. Sood and Meeser talk with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the treatment methods that have brought them the most success for their patients.

Henry Anhalt, DO (left), is a pediatric endocrinologist in Hackensack, NJ who was most recently the Chief Medical Officer of the T1D Exchange, a nonprofit organization that has created a new paradigm fostering collaboration among patients, physicians, researchers and industry to speed discovery of better therapies for type 1 diabetes. Howard Steinberg went from brand management at the Pepsi Cola Co to applying his personal understanding of diabetes - he has lived with type 1 diabetes since age 10 - to create the multimedia DTC platform dLife, which he founded in 2005.

In this Exclusive Interview, Henry Anhalt and Howard Steinberg talk with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about the work of Insulin for Life USA, an affiliate of the global organization that works to bring much-needed insulin to those in need in developing countries.